Cargando…
Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early–intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial
BACKGROUND/OBJECTIVE: The survival benefit of treatment for unresectable hepatocellular carcinoma (HCC) with transcatheter arterial chemoembolization (TACE) combined with sorafenib remains uncertain. We compared the survival of patients treated with TACE and sorafenib with that of patients treated w...
Autores principales: | Lee, Teng-Yu, Lin, Chen-Chun, Chen, Chiung-Yu, Wang, Tsang-En, Lo, Gin-Ho, Chang, Chi-Sen, Chao, Yee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604624/ https://www.ncbi.nlm.nih.gov/pubmed/28906355 http://dx.doi.org/10.1097/MD.0000000000007655 |
Ejemplares similares
-
Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate–advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes
por: Xie, Yong, et al.
Publicado: (2021) -
Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization: A retrospective analysis of 509 cases
por: Shen, Hujia, et al.
Publicado: (2017) -
Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib
por: Fu, Sirui, et al.
Publicado: (2016) -
Transcatheter Arterial Chemoembolization With Gelatin Sponge Microparticles Treated for BCLC Stage B Hepatocellular Carcinoma: A Single Center Retrospective Study
por: Kamran, Asad Ullah, et al.
Publicado: (2015) -
350–560 μm gelatin sponge particles combined with transcatheter arterial chemoembolization for the treatment of elderly hepatocellular carcinoma: The safety and efficacy
por: Zhao, Guang Sheng, et al.
Publicado: (2017)